Dario Trapani, Medical Oncologist at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“Excited to share that at ESMO25, with Giulia Segafredo and Paul Ruff, we will present our study on cost-effectiveness thresholds CEA for first-line immunotherapy in advanced NSCLC (PD-L1 ≥50%) in South Africa.
Key points:
ICIs are now on the WHO Essential Medicines List EML, but current prices far exceed cost-effectiveness thresholds in LMICs.
We modeled alternative dosing strategies – standard flat dose, reduced flat dose, and weight-based dose with vial sharing – to explore feasible ways to improve affordability.
We will show how and to what extent dose optimization and strategic discounts could make novel cancer medicines without compromising clinical efficacy, providing a quantitative framework for policymakers and healthcare systems to make evidence-based decisions on immunotherapy access ICI
Join us at ESMO25 to see how innovative approaches can bridge the gap between essential medicines and patient access.”
More posts featuring Dario Trapani.